Clinical and immunological evaluation of anti-apoptosis protein survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer

摘要

BackgroundWe previously reported that survivin-2B, a splicing variant of survivin, was expressed in various types of tumors and that survivin-2B peptide might serve as a potent immunogenic cancer vaccine. The objective of this study was to examine the toxicity of and to >clinically and immunologically evaluate survivin-2B peptide in a phase I clinical study for patients with advanced or recurrent breast cancer.